AU2001266223A1 - Methods and compositions for the treatment of alcoholism and alcohol dependence - Google Patents

Methods and compositions for the treatment of alcoholism and alcohol dependence

Info

Publication number
AU2001266223A1
AU2001266223A1 AU2001266223A AU6622301A AU2001266223A1 AU 2001266223 A1 AU2001266223 A1 AU 2001266223A1 AU 2001266223 A AU2001266223 A AU 2001266223A AU 6622301 A AU6622301 A AU 6622301A AU 2001266223 A1 AU2001266223 A1 AU 2001266223A1
Authority
AU
Australia
Prior art keywords
alcoholism
compositions
treatment
methods
alcohol dependence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001266223A
Inventor
Abdulla Abu-Bakr Badawy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardiff & Vale National Health Service Trust
Original Assignee
Cardiff & Vale Nat Health Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0016056A external-priority patent/GB0016056D0/en
Priority claimed from GB0017345A external-priority patent/GB0017345D0/en
Application filed by Cardiff & Vale Nat Health Serv filed Critical Cardiff & Vale Nat Health Serv
Publication of AU2001266223A1 publication Critical patent/AU2001266223A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Use is disclosed of (a) an AlDH-inhibitory amount of a Trp metabolite, or an analogue or derivative thereof or (b) a bioprecursor thereof, or (c) a potentiator of (a) and/or (b), in the preparation of a medicament for treating alcoholism and/or alcohol dependence.
AU2001266223A 2000-06-30 2001-07-02 Methods and compositions for the treatment of alcoholism and alcohol dependence Abandoned AU2001266223A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0016056 2000-06-30
GB0016056A GB0016056D0 (en) 2000-06-30 2000-06-30 Methods and compositions for the treatment of alcoholism and alcohol dependence
GB0017345A GB0017345D0 (en) 2000-07-15 2000-07-15 Methods and compositions for the treatment of alcoholism and alcohol dependence
GB0017345 2000-07-15
PCT/GB2001/002930 WO2002002091A2 (en) 2000-06-30 2001-07-02 Methods and compositions for the treatment of alcoholism and alcohol dependence

Publications (1)

Publication Number Publication Date
AU2001266223A1 true AU2001266223A1 (en) 2002-01-14

Family

ID=26244570

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001266223A Abandoned AU2001266223A1 (en) 2000-06-30 2001-07-02 Methods and compositions for the treatment of alcoholism and alcohol dependence

Country Status (7)

Country Link
US (1) US8003704B2 (en)
EP (1) EP1294377B1 (en)
JP (1) JP2004501963A (en)
AT (1) ATE528000T1 (en)
AU (1) AU2001266223A1 (en)
ES (1) ES2375347T3 (en)
WO (1) WO2002002091A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0326477D0 (en) * 2003-11-13 2003-12-17 Shs Int Ltd Medicaments for use in promoting and maintaining abstinence
BRPI0820440A2 (en) * 2007-11-06 2015-05-26 Cv Therapeutics Inc Aldh-2 inhibitors in the treatment of psychiatric disorders.
WO2018071814A1 (en) 2016-10-14 2018-04-19 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1172154B (en) * 1981-12-15 1987-06-18 Manetti & Roberts Italo Brit PIROGLUTAMMIL-TRIPTOFANO AND ITS DERIVATIVES, PROCEDURE FOR ITS PREPARATION AND THERAPEUTIC APPLICATIONS
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
GB9522615D0 (en) * 1995-11-03 1996-01-03 Pharmacia Spa 4-Phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity
DE69932427T2 (en) 1998-05-12 2007-02-22 The Endowment for Research in Human Biology, Inc., Boston METHOD AND TESTS USEFUL IN THE TREATMENT OF ALCOHOL DEPENDENCY OR ABUSE

Also Published As

Publication number Publication date
WO2002002091A3 (en) 2002-05-02
ATE528000T1 (en) 2011-10-15
ES2375347T3 (en) 2012-02-29
US8003704B2 (en) 2011-08-23
EP1294377B1 (en) 2011-10-12
WO2002002091A2 (en) 2002-01-10
JP2004501963A (en) 2004-01-22
EP1294377A2 (en) 2003-03-26
US20080076796A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
WO2003002136A3 (en) Stable formulation of modified glp-1
AU2002258066A1 (en) Dermatological and cosmetic compositions
AU2002235930A1 (en) A process for the manufacture of a herbal composition comprising a matrine
AU2003206183A1 (en) Composition containing moutan root bark extract as active ingredient
NZ515392A (en) Respiratory syncytial virus replication inhibitors
DE50015623D1 (en) KOVALENT BROKEN INSULINDIMERE
WO2003030819A3 (en) Tetracycline derivatives and methods of use thereof
WO2002069945A3 (en) Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors
WO2004064735A3 (en) Treatment of benign prostatic hyperplasia
WO2003028715A3 (en) Methods using 1, 2-dithiol-3-thiones and their derivatives and metabolites for inhibiting angiogenesis
AU4671101A (en) Formulation for the prevention of cardiovascular disease
EP1262196A3 (en) Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
WO2002000183A3 (en) Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin
WO2004112771A8 (en) Pharmaceutical compositions including an antihistamine and a stimulant and use thereof
AU4651700A (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
WO2001074394A8 (en) New combination of a betablocker and a cholesterol-lowering agent
AU2002327418A1 (en) Taste masking composition
AU2001266223A1 (en) Methods and compositions for the treatment of alcoholism and alcohol dependence
WO2003084503A3 (en) P38 kinase inhibitors for treating mucus hypersecretion_
GB2393666A (en) Apparatus for use in exercising
MXPA03010672A (en) Therapeutic compositions for repairing chondropathy.
CA2505500A1 (en) Method of stimulating hair growth using benzopyrans
WO2002062952A3 (en) Non-cytotoxic pap mutants
CA2467265A1 (en) Pharmaceutical composition for enhancing immunity, and extract of poria
AU2003249472A1 (en) Use of angelicin and of its structural analogues for the treatment of thalassemia